An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...
Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably ...
The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary ...
Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer Cancer incidence and survival were ...
Older fathers’ sperm carry more harmful mutations, raising children’s genetic risks. Discover how age impacts DNA and ...
Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
– Approval is based on Phase III INAVO120 results, showing the Itovebi TM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback